Toward this end,our group has described the design of 3pRNA prodrugs that employ bulkycovalently linked macromolecules (e.g, PEG) to block recognition of3pRNA by RIG-I until they are removed under a specific environmentalstimulus (e.g., enzymes, redox).53 Likewise,there is a deep nanomedicine toolbox available for improving cargodelivery to tumor sites, including improving SLR-LNP half-life and/orintegration of molecular targeting moieties or “sheddable”coronas, which could be harnessed to expand the therapeutic windowof systemically administered RIG-I agonists. Here, RIGI is linked to neoplasm.